BusinessTimes.top
BusinessTimes is for folks who likes to get updated before others about latest news of Stock Markets, Business News, Personal Funds, Currencies and Much More. If you have any kind of questions, please feel free to ask by contacting us.

Forty Seven and Rocket Collaborate for Fanconi Anemia Research

Forty Seven and Rocket have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven’s novel conditioning regimen with Rocket’s stem cell gene therapy.

Forty Seven (NASDAQ:FTSV) and Rocket Pharmaceuticals (NASDAQ:RCKT) have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven’s novel antibody-based conditioning regimen with Rocket’s stem cell gene therapy.

As quoted in the press release:

The initial collaboration will evaluate this treatment regimen in Fanconi Anemia (FA), a genetic disease that affects patients’ capacity to produce blood cells and is associated with an increased risk of leukemia and other neoplasms. RP-L102, Rocket’s gene therapy approach for FA, involves treatment with patients’ own gene-corrected blood forming stem cells (hematopoietic stem cells, or HSCs).

Gene therapies for monogenic blood disorders have broad potential. One concern associated with these treatments is the toxicity of pre-therapy conditioning regimens that utilize cytotoxic chemotherapy and/or radiation to destroy existing HSCs and facilitate engraftment of gene-corrected HSCs.

Click here to read the full press release.

Pharmaceutical 2020 Market Outlook Cover

Should you invest in the 2020 pharmaceutical market?

Read our FREE outlook report!

 

You might also like

Comments are closed.